Charles River Automates Endotoxin Testing Cartridge Production, Boosts Capacity and Quality
Event summary
- Charles River's Endosafe® Cartridge Technology Automated Manufacturing Suite reached full operational capacity in Q3 2026.
- Automation reduced scrap rates by 2%, invalid cartridge rates by 13%, and increased production capacity by 14%.
- Labor productivity improved by 87%, enabling higher throughput with fewer resources.
- The suite enables full inspections of every cartridge, enhancing quality control and traceability.
The big picture
Charles River's automation of endotoxin testing cartridge production aligns with broader industry trends toward digital traceability and advanced manufacturing technologies. The move strengthens the company's position in the biotechnology and pharmaceutical services sectors, where quality control and operational efficiency are critical. The automation suite's ability to inspect every cartridge sets a new standard for manufacturing consistency and supply chain quality.
What we're watching
- Operational Efficiency
- How Charles River will sustain the 87% labor productivity improvement while scaling production.
- Market Demand
- Whether the 14% increase in production capacity will be sufficient to meet growing global customer demand.
- Innovation Pace
- The pace at which Charles River can redirect skilled employees to higher-value initiatives following automation.
Related topics